| |
Management Team
Ceres has developed a strong central management team that brings together sophisticated business managers, experienced regulatory counsel, and industry-leading scientists.
Tom Dunlap - Chief Executive Officer
Ross Dunlap - Chief Operating Officer
Dr. Joseph Weaver - Medical Director
Dr. Barney Bishop - Science Director
Dr. Alessandra Luchini - Science Director
Thomas M. Dunlap
Chief Executive Officer
Tom is a founding member of Ceres. He brings a unique mix of leadership and business experience combined with Intellectual Property expertise in high-technology and scientific applications. Tom is serving as the interim CEO at company start-up, supporting capital funding, marketing and sales development, and industry collaboration activities. Tom has 10 years of experience as a lawyer working with start-up technology companies and has represented clients in a variety of complex business and intellectual property matters, including multi-jurisdictional federal patent infringement and invalidity claims. Before becoming an attorney, Tom worked in New York in both retail and commercial banking. Tom also serves as a Captain in the Army National Guard.
|
Ross M. Dunlap
Chief Operating Officer
Ross is a founding member of Ceres Nanosciences and has been driving the strategic business planning and core operational activities of Ceres. Ross is responsible for directing core operational activities, product definition and development, customer sales and management, and all business collaborations and partnerships. Ross has over 12 years of experience working in operational and strategic business consulting. He began his career with Arthur Andersen's Business Consulting practice, working with many of the DC region's leading start-up technology companies, developing solutions to establish and maintain core business operations. Ross has spent the last five years with Washington Consulting, Inc., a DC based consulting firm, which he helped start up and grow from a three person project into a 100 person operation that was acquired by a major defense contractor. Throughout his consulting career, Ross has worked across a range of industries, technologies, and processes to help organizations successfully achieve operational capability and profitability.
|
Dr. Joseph Weaver
Chief Medical Officer
Dr. Weaver brings over 40 years of experience from a long and distinguished career in cancer-related research and treatment programs. As Chief Medical Officer for Ceres, he will lend his extensive experience as a medical practitioner and business entrepreneur to drive the development of Ceres' core operations and its product development. Dr. Weaver is board certified by the American Board of Internal Medicine in Internal Medicine, Hematology, and Medical Oncology, and by the American Board of Radiology in Radiation Oncology. He is a life member of AMA and holds fellowships in the American College of Physicians and American College of Radiation Oncology. He was a clinical professor of Internal Medicine at the Pensacola Educational Program, and a clinical professor of Radiation Oncology at Eastern Virginia School of Medicine in Norfolk, VA. Since 1993, he has been the Director of Radiation Oncology at Baptist and Gulf Breeze Hospitals in Pensacola, FL. Dr. Weaver has been the head of the Cancer Committee for most of that period, participating in multiple clinical trials both locally, and through an affiliation with H. Lee Moffitt Cancer Center in Tampa, FL. During his tenure in Pensacola, Dr. Weaver cofounded, operated and has continued as a co-partner in a group of four cancer centers in South Alabama, collectively called Gulf Coast Cancer Centers in Foley, Brewton, Monroeville, and Gulf Shores, AL. He also independently founded the South Alabama Oncology Center in Opp, AL.
|
Dr. Barney Bishop
Science Co-Director
As a Director of Science for Ceres, Dr. Bishop provides technical guidance and expertise to key components of the scientific operations of Ceres. This includes the development of the lab facilities and operations, the management of the Nanotrap® production, and the general support of ongoing lab operations. Dr. Bishop will also establish and manage the Research and Development function of Ceres and will be a key driver in the development of new applications for the Nanotrap®. Dr. Bishop is currently a professor of General Biology and Protein Biochemistry at George Mason University. Dr. Bishop received a Ph.D. in chemistry from the University of North Carolina at Chapel Hill in 1997, where his graduate research focused on peptide synthesis and engineering. After receiving his doctorate, Dr. Bishop joined the laboratory of Dr. Lynne Regan at Yale University as a postdoctoral associate in order to continue his education and gain experience in the areas of molecular biology, protein engineering and protein biophysical characterization. His research focused on reengineering helical bundle proteins in order to enhance their stability. In the spring of 2001, Dr Bishop joined New River Pharmaceuticals as a Senior Research Scientist. During his time at New River Pharmaceuticals, Dr. Bishop played a major role in the design and assembly of product lead candidates. He joined the Department of Chemistry and Biochemistry at George Mason University in the fall of 2003. His current research interests include molecular engineering, antimicrobial peptides and the design of novel therapeutic agents for combating infection, In 2007, Dr. Bishop joined the scientific advisory board for Kempharm, Inc., an early-phase biopharmaceutical company focused on the development of new and safer treatments for pain, AD/HD and other illnesses.
|
Dr. Alessandra Luchini
Science Co-Director
As a Director of Science for Ceres, Dr. Luchini provides technical guidance and expertise to key components of the scientific operations of Ceres. This includes the development of the lab facilities and operations, the management of the Nanotrap® production, and the general support of ongoing lab operations. Dr. Luchini will also establish and manage the Research and Development function of Ceres and will be a key driver in the development of new applications for the Nanotrap®. Dr. Luchini is currently a Research Professor at George Mason University. She obtained her doctorate from the University of Padova in Italy in 2005. She has worked as a research fellow for Department of Biotechnology and Bioscience at the University of Milano-Bicocca, in Milano, Italy and as a Teaching Assistant at the University of Milano-Bicocca, Master in Molecular Immunopathology. She has published a number of peer reviewed articles and has been working with CAPMM since 2004. |
|
